Chiun Hsu

18.5k total citations · 3 hit papers
226 papers, 7.4k citations indexed

About

Chiun Hsu is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chiun Hsu has authored 226 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 92 papers in Hepatology and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chiun Hsu's work include Hepatocellular Carcinoma Treatment and Prognosis (84 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Pancreatic and Hepatic Oncology Research (32 papers). Chiun Hsu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (84 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Pancreatic and Hepatic Oncology Research (32 papers). Chiun Hsu collaborates with scholars based in Taiwan, United States and South Korea. Chiun Hsu's co-authors include Ann‐Lii Cheng, Ying‐Chun Shen, Chih‐Hung Hsu, Yu‐Yun Shao, Masatoshi Kudo, Da‐Liang Ou, Su Pin Choo, Stephen L. Chan, Zhong‐Zhe Lin and Pei‐Jer Chen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chiun Hsu

221 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

2018 416 citations Chiun Hsu et al. profile →
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

2020 386 citations Ann‐Lii Cheng, Chiun Hsu et al. Journal of Hepatology profile →
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

2017 300 citations Chiun Hsu et al. profile →

Peers

Countries citing papers authored by Chiun Hsu

Since Specialization

Citations

This map shows the geographic impact of Chiun Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiun Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiun Hsu more than expected).

Fields of papers citing papers by Chiun Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiun Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiun Hsu. The network helps show where Chiun Hsu may publish in the future.

Co-authorship network of co-authors of Chiun Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Chiun Hsu. A scholar is included among the top collaborators of Chiun Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiun Hsu. Chiun Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New targets and new drugs for hepatobiliary cancers 2025 ·Journal of Hepatology ·Stephen L. Chan, (unknown), Chiun Hsu, Víctor Moreno, Landon L. Chan, Bridget P. Keenan	2
2	Regorafenib enhances M1/M2 macrophage polarization by inhibiting the secretion of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma 2024 ·Life Sciences ·Yu‐Hsin Chen, (unknown), Da‐Liang Ou, Chia‐Lang Hsu, Chiun Hsu, Chun‐Nan Chen, Jenq‐Yuh Ko, Ching‐Ting Tan	0
3	Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma 2023 ·Cancer Letters ·Zhong‐Zhe Lin, Mickey C.‐T. Hu, Chiun Hsu, Yao‐Ming Wu, Yen‐Shen Lu, Ja‐an Annie Ho, Shiou‐Hwei Yeh, Pei‐Jer Chen, Ann‐Lii Cheng	7
4	Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy 2023 ·Cancer Immunology Research ·(unknown), Chia‐Lang Hsu, (unknown), Da‐Liang Ou, Chiun Hsu, Ching‐Ting Tan	9
5	Deriving and Validating an Instrument for Assessing Students' Perspectives on a Completely Digital Problem-based Learning Curriculum during COVID-19 2020 ·Chia‐Ter Chao, (unknown), (unknown), Jeng‐Yi Shieh, Huey‐Ling Chen, Chiun Hsu, (unknown), Mong‐Wei Lin	2
6	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy 2020 ·The Oncologist ·Zhong‐Zhe Lin, Bang‐Bin Chen, Yi‐Ping Hung, (unknown), Ying‐Chun Shen, Yu‐Yun Shao, Chih‐Hung Hsu, Ann‐Lii Cheng, Rheun‐Chuan Lee, Yee Chao, Chiun Hsu	17
7	Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040 2017 ·UCL Discovery (University College London) ·Bruno Sangro, Ignacio Melero, (unknown), Chiun Hsu, Mitsuhiro Kudo, Tae‐Yop Kim, (unknown), Jörg Trojan, (unknown), T Meyer, Y-K. Kang, Winnie Yeo, Arun Chopra, (unknown), Christine Dela Cruz, Hui Zhao, Jaclyn Neely, (unknown), (unknown)	12
8	Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis 2017 ·International Journal of Gynecological Pathology ·Emily Han-Chung Hsiue, Chiun Hsu, Li‐Hui Tseng, Tzu‐Pin Lu, Kuan‐Ting Kuo	12
9	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma 2016 ·European Radiology ·Bang‐Bin Chen, Chao‐Yu Hsu, Chih‐Wei Yu, Po‐Chin Liang, Chiun Hsu, Chih‐Hung Hsu, Ann‐Lii Cheng, Tiffany Ting‐Fang Shih	17
10	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression 2015 ·Clinical Cancer Research ·Chiun Hsu, Liang‐In Lin, Yu‐Che Cheng, (unknown), Yu‐Yun Shao, Ann‐Lii Cheng, Da‐Liang Ou	40
11	Gap in the Intensity of End-of-Life Care between Younger and Older Taiwanese Adult Cancer Patients may not Reflect Younger Patients’ Preferences 2015 ·SHILAP Revista de lepidopterología ·(unknown), Tsang‐Wu Liu, Jyh‐Ming Chow, Chang‐Fang Chiu, Chiun Hsu, Li‐Ni Liu, Su‐Ching Kuo	2
12	H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis 2014 ·Cancer Research ·Pei‐Chun Wu, Jeng‐Wei Lu, Jer‐Yen Yang, I‐Hsuan Lin, Da‐Liang Ou, Yu‐Hsiang Lin, (unknown), Wenfeng Huang, Wan-Ping Wang, Yih‐Leh Huang, Chiun Hsu, Liang‐In Lin, Yueh‐Min Lin, Chieh‐Yu Shen, Tsai‐Yu Tzeng	56
13	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma 2014 ·Clinical Cancer Research ·Ho Yeong Lim, Jeong Heo, Hye Jin Choi, Cheng-Yao Lin, Jung‐Hwan Yoon, Chiun Hsu, Kun‐Ming Rau, Ronnie T. P. Poon, Winnie Yeo, Joong‐Won Park, Miah Hiang Tay, Wen-Son Hsieh, Christian Kappeler, Prabhu Rajagopalan, Heiko Krissel, Michael Jeffers, Chia‐Jui Yen, Won Young Tak	86
14	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials 2011 ·Oncology ·Shih‐Hung Yang, Yu‐Hsuan Kuo, Yu‐Wen Tien, Chiun Hsu, Chih‐Hung Hsu, Sung‐Hsin Kuo, Ann‐Lii Cheng	13
15	Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells 2010 ·Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Sung‐Liang Yu, Kuen‐Feng Chen, (unknown), (unknown), Wen-Chi Feng, (unknown), Liang‐In Lin, Chiun Hsu, Ann‐Lii Cheng	68
16	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma 2009 ·Clinical Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Ja‐Der Liang, Jun‐Yang Liou, Sung‐Liang Yu, (unknown), Dasheng Wang, Yen‐Shen Lu, Chiun Hsu, Ann‐Lii Cheng	36
17	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial 2008 ·Hepatology ·Chiun Hsu, Chao A. Hsiung, Ih‐Jen Su, Wei-Shou Hwang, Ming-Chung Wang, Sheng-Fung Lin, (unknown), Hui-Hua Hsiao, (unknown), Ming-Chih Chang, Yu-Min Liao, Chi-Cheng Li, (unknown), Hwei‐Fang Tien, Tsu-Yi Chao, Tsang-Wu Liu, Ann‐Lii Cheng, Pei‐Jer Chen	230
18	In Vivo Efficacy of Nemonoxacin in a Mouse Pulmonary Infection Model 2008 ·46th Annual Meeting ·Chiun Hsu	5
19	Potential synergistic anti-tumor effects between sorafenib and the MEK inhibitor CI1040 in hepatocellular carcinoma (HCC) 2008 ·Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Sung‐Liang Yu, Wei-Chung Allen Lee, (unknown), Chiun Hsu, Ann‐Lii Cheng	1
20	Alcoholism and Alcoholic Organ Damage and Genetic Polymorphisms of Alcohol Metabolizing Enzymes in Chinese Patients 1997 ·Hepatology ·You‐Chen Chao, Ton-Ho Young, Haoning Tang, Chiun Hsu	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact